Free Trial

Liquidia Q3 2023 Earnings Report

Liquidia logo
$11.10 +0.51 (+4.82%)
(As of 12/20/2024 05:31 PM ET)

Liquidia EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Liquidia Revenue Results

Actual Revenue
$3.68 million
Expected Revenue
$4.55 million
Beat/Miss
Missed by -$870.00 thousand
YoY Revenue Growth
N/A

Liquidia Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Liquidia Earnings Headlines

Liquidia initiated with an Overweight at Wells Fargo
Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $24.00
This Indicator called BOTH NVDA rallies
Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…
Liquidia Technologies (LQDA) Gets a Buy from Scotiabank
See More Liquidia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia and other key companies, straight to your email.

About Liquidia

Liquidia (NASDAQ:LQDA), a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

View Liquidia Profile

More Earnings Resources from MarketBeat

Upcoming Earnings